Section Arrow
TOVX.NYSE-M
- Theriva Biologics Inc
Quotes are at least 15-min delayed:2026/05/31 02:58 EDT
Regular Hours
Last
 0.2838
-0.0252 (-8.16%)
Day High 
0.309 
Prev. Close
0.309 
1-M High
0.3899 
Volume 
1.70M 
Bid
0.2775
Ask
0.29
Day Low
0.2735 
Open
0.309 
1-M Low
0.2615 
Market Cap 
14.18M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.3 
20-SMA 0.33 
50-SMA 0.29 
52-W High 0.8632 
52-W Low 0.1628 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.58/-0.22
Enterprise Value
16.20M
Balance Sheet
Book Value Per Share
0.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1172-0.0468-28.54%-- 
REPLReplimune Group8.69+4.01+85.68%-- 
CDTCDT Equity Inc.1.04+0.0899+9.46%-- 
CMNDClearmind Medicine Inc.3.58+1.13+46.12%-- 
OTLKOutlook Therapeutics0.73-0.01-1.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.